December 15, 2016—Sen. Charles Grassley (R-Iowa) is urging President-elect Trump to work with Congress to deal with drug companies that game the system and engage in anti-competitive behavior. The Justice Department, meanwhile, has charged two drug company executives with conspiracy to fix prices, rig bids, and allocate customers, part of a broader investigation of white collar crime by generic drug manufacturers.
You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register. Already registered? Click here to login. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)